Cytomegalovirus reactivation in critically ill immunocompetent hosts: A decade of progress and remaining challenges

Antiviral Research

Volumn 90, Issue 3, 2011, Pages 151-159

  Cook, Charles H ^a   Trgovcich, Joanne ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Critical illness; Cytomegalovirus; Immunocompetent host; Murine models; Reactivation

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR; VALGANCICLOVIR;

CRITICALLY ILL PATIENT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; EXPERIMENTAL MODEL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENCE; NONHUMAN; PRIORITY JOURNAL; REINFECTION; REVIEW; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS VIRULENCE;

ANIMALS; CRITICAL ILLNESS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; VIRUS ACTIVATION;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5; MURINAE;

EID: 79953845067     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.03.179     Document Type: Review

References (147)

1. Adler S.P. Human CMV vaccine trials: What if CMV caused a rash?. J. Clin. Virol. 2008, 41:231-236.
2. Adler S.P., Baggett J., McVoy M. Transfusion-associated cytomegalovirus infections in seropositive cardiac surgery patients. Lancet 1985, 326:743-746.
3. Almanzar G., Schwaiger S., Jenewein B., Keller M., Herndler-Brandstetter D., Wurzner R., Schonitzer D., Grubeck-Loebenstein B. Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J. Virol. 2005, 79:3675-3683.
4. Andrews D.M., Estcourt M.J., Andoniou C.E., Wikstrom M.E., Khong A., Voigt V., Fleming P., Tabarias H., Hill G.R., van der Most R.G., Scalzo A.A., Smyth M.J., Degli-Esposti M.A. Innate immunity defines the capacity of antiviral T cells to limit persistent infection. J. Exp. Med. 2010, 207:1333-1343.
5. Babel N., Brestrich G., Gondek L.P., Sattler A., Wlodarski M.W., Poliak N., Bethke N., Thiel A., Hammer M.H., Reinke P., Maciejewski J.P. Clonotype analysis of cytomegalovirus-specific cytotoxic T lymphocytes. J. Am. Soc. Nephrol. 2009, 12:344-352.
6. Babić M., Pyzik M., Zafirova B., Mitrović M., Butorac V., Lanier L.L., Krmpotić A., Vidal S.M., Jonjić S. Cytomegalovirus immunoevasin reveals the physiological role of " missing self" recognition in natural killer cell dependent virus control in vivo. J. Exp. Med. 2010, 207:2663-2673.
7. Balthesen M., Messerle M., Reddehase M.J. Lungs are a major organ site of cytomegalovirus latency and recurrence. J. Virol. 1993, 67:5360-5366.
8. Barry S.M., Johnson M.A., Janossy G. Cytopathology or immunopathology? The puzzle of cytomegalovirus pneumonitis revisited. Bone Marrow Transplant. 2000, 26:591-597.
9. Biron K.K. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 2006, 71:154-163.
10. Bolovan-Fritts C.A., Trout R.N., Spector S.A. High T-cell response to human cytomegalovirus induces chemokine-mediated endothelial cell damage. Blood 2007, 110:1857-1863.
11. Bruynseels P., Jorens P.G., Demey H.E., Goossens H., Pattyn S.R., Elseviers M.M., Weyler J., Bossaert L.L., Mentens Y., Ieven M. Herpes simplex virus in the respiratory tract of critical care patients: a prospective study. Lancet 2003, 362:1536-1541.
12. Camps K., Jorens P., Demey H., Pattyn S., Ieven M. Clinical significance of herpes simplex virus in the lower respiratory tract of critically ill patients. Eur. J. Clin. Microbiol. Infect. Dis. 2002, 21:758-759.
13. Cannon M.J., Openshaw P.J., Askonas B.A. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J. Exp. Med. 1988, 168:1163-1168.
14. Chen H.D., Fraire A.E., Joris I., Brehm M.A., Welsh R.M., Selin L.K. Memory CD8+ T cells in heterologous antiviral immunity and immunopathology in the lung. Nat Immunol 2001, 2:1067-1076.
15. Cheung K.S., Lang D.J. Transmission and activation of cytomegalovirus with blood transfusion: a mouse model. J. Infect. Dis. 1977, 135:841-845.
16. Chiche L., Forel J.M., Roch A., Guervilly C., Pauly V., Allardet-Servent J., Gainnier M., Zandotti C., Papazian L. Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients. Crit. Care. Med. 2009, 37:1850-1857.
17. Chilet M., Aguilar G., Benet I., Belda J., Tormo N., Carbonell J.A., Clari M.A., Costa E., Navarro D. Virological and immunological features of active cytomegalovirus infection in nonimmunosuppressed patients in a surgical and trauma intensive care unit. J. Med. Virol. 2010, 82:1384-1391.
18. Collins T., Pomeroy C., Jordan M.C. Detection of latent cytomegalovirus DNA in diverse organs of mice. J. Infect. Dis. 1993, 168:725-729.
19. Cook C. Cytomegalovirus reactivation and mortality during critical illness: a $64, 000 question. Crit. Care Med. 2009, 37:2475-2476.
20. Cook C., Zhang X., McGuinness B., Lahm M., Sedmak D., Ferguson R. Intra-abdominal bacterial infection reactivates latent pulmonary cytomegalovirus in immunocompetent mice. J. Infect. Dis. 2002, 185:1395-1400.
21. Cook C.H. Cytomegalovirus reactivation in " immunocompetent" patients: a call for scientific prophylaxis. J. Infect. Dis. 2007, 196:1273-1275.
22. Cook C.H., Martin L.C., Yenchar J.K., Lahm M.C., McGuinness B., Davies E.A., Ferguson R.M. Occult herpes family viral infections are endemic in critically ill surgical patients. Crit. Care Med. 2003, 31:1923-1929.
23. Cook C.H., Trgovcich J., Zimmerman P.D., Zhang Y., Sedmak D.D. Lipopolysaccharide, tumor necrosis factor alpha, or interleukin-1{beta} triggers reactivation of latent cytomegalovirus in immunocompetent mice. J. Virol. 2006, 80:9151-9158.
24. Cook C.H., Yenchar J.K., Kraner T.O., Davies E.A., Ferguson R.M. Occult herpes family viruses may increase mortality in critically ill surgical patients. Am. J. Surg. 1998, 176:357-360.
25. Cook C.H., Zhang Y., Sedmak D.D., Martin L.C., Jewell S., Ferguson R.M. Pulmonary cytomegalovirus reactivation causes pathology in immunocompetent mice. Crit. Care Med. 2006, 34:842-849.
26. Curtsinger L.J., Cheadle W.G., Hershman M.J., Cost K., Polk J., Hiram C. Association of cytomegalovirus infection with increased morbidity is independent of transfusion. Am. J. Surg. 1989, 158:606-611.
27. Cushing D., Elliot S., Caplan E., Batlas S., Sridhara R., Wade J. Herpes simplex virus and cytomegalovirus excretion associated with increased ventilator days in trauma patients. J. Trauma 1993, 25:161.
28. Desachy A., Ranger-Rogez S., Francois B., Venot C., Traccard I., Gastinne H., Denis F., Vignon P. Reactivation of human herpesvirus type 6 in multiple organ failure syndrome. Clin. Infect. Dis. 2001, 32:197-203.
29. Döcke W.D., Kiessling C., Worm M., Friedrich M., Pruss A., Weitz M., Prösch S., Kern F., Volk H.D., Sterry W., Asadullah K. Subclinical activation of latent cytomegalovirus (CMV) infection and anti-CMV immune response in patients with atopic dermatitis. Br. J. Dermatol. 2003, 148:954-963.
30. Docke W.D., Prosch S., Fietze E., Kimel V., Zuckermann H., Klug C., Syrbe U., Kruger D.H., von Baehr R., Volk H.D. Cytomegalovirus reactivation and tumour necrosis factor. Lancet 1994, 343:268-269.
31. Domart Y., Trouillet J.L., Fagon J.Y., Chastre J., Brun-Vezinet F., Gibert C. Incidence and morbidity of cytomegaloviral infection in patients with mediastinitis following cardiac surgery. Chest 1990, 97:18-22.
32. Drew W.L., Miner R.C. Transfusion-related cytomegalovirus infection following noncardiac surgery. JAMA 1982, 247:2389-2391.
33. Dropulic L.K., Cohen J.I. Update on new antivirals under development for the treatment of double-stranded DNA virus infections. Clin. Pharmacol. Ther. 2010, 88:610-619.
34. Eisenfeld L., Silver H., McLaughlin J., Klevjer-Anderson P., Mayo D., Anderson J., Herson V., Krause P., Savidakis J., Lazar A. Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood. Transfusion 1992, 32:205-209.
35. Fietze E., Prosch S., Reinke P., Stein J., Docke W.D., Staffa G., Loning S., Devaux S., Emmrich F., von Baehr R. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor. Transplantation 1994, 58:675-680.
36. Forster M.R., Bickerstaff A.A., Wang J.-J., Zimmerman P.D., Cook C.H. Allogeneic stimulation causes transcriptional reactivation of latent murine cytomegalovirus. Transplant. Proc. 2009, 41:1927-1931.
37. Forster M.R., Trgovcich J., Zimmerman P., Chang A., Miller C., Klenerman P., Cook C.H. Antiviral prevention of sepsis induced cytomegalovirus reactivation in immunocompetent mice. Antiviral Res. 2010, 85:496-503.
38. Gaytant M.A., Steegers E.A., Semmekrot B.A., Merkus H.M., Galama J.M. Congenital cytomegalovirus infection: review of the epidemiology and outcome. Obstet. Gynecol. Surv. 2002, 57:245-256.
39. Gilbert C., Bestman-Smith J., Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Updat. 2002, 5:88-114.
40. Gillespie G.M., Wills M.R., Appay V., O'Callaghan C., Murphy M., Smith N., Sissons P., Rowland-Jones S., Bell J.I., Moss P.A. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J. Virol. 2000, 74:8140-8150.
41. Glaser R., Friedman S.B., Smyth J., Ader R., Bijur P., Brunell P., Cohen N., Krilov L.R., Lifrak S.T., Stone A., Toffler P. The differential impact of training stress and final examination stress on herpesvirus latency at the United States Military Academy at West Point. Brain Behavior Immunity 1999, 13:240-251.
42. Glaser R., Pearl D.K., Kiecolt-Glaser J.K., Malarkey W.B. Plasma cortisol levels and reactivation of latent Epstein-Barr virus in response to examination stress. Psychoneuroendocrinology 1994, 19:765-772.
43. Glaser R., Pearson G.R., Jones J.F., Hillhouse J., Kennedy S., Mao H., Kiecolt-Glaser J.K. Stress-related activation of Epstein-Barr virus. Brain Behavior Immunity 1991, 5:219-232.
44. Gonczol E., Danczig E., Boldogh I., Toth T., Vaczi L. In vivo model for the acute, latent and reactivated phases of cytomegalovirus infection. Acta Microbiol. Hung. 1985, 32:39-47.
45. Gor D., Sabin C., Prentice H.G., Vyas N., Man S., Griffiths P.D., Emery V.C. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant. 1998, 21:597-605.
46. Gorman S., Harvey N.L., Moro D., Lloyd M.L., Voigt V., Smith L.M., Lawson M.A., Shellam G.R. Mixed infection with multiple strains of murine cytomegalovirus occurs following simultaneous or sequential infection of immunocompetent mice. J. Gen. Virol. 2006, 87:1123-1132.
47. Gorzer I., Guelly C., Trajanoski S., Puchhammer-Stockl E. Deep sequencing reveals highly complex dynamics of human cytomegalovirus genotypes in transplant patients over time. J. Virol. 2010, 84:7195-7203.
48. Griffiths P.D. Cytomegalovirus in intensive care. Rev. Med. Virol. 2010, 20:1-3.
49. Grundy J.E., Shanley J.D., Griffiths P.D. Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition?. Lancet 1987, 2:996-999.
50. Halpern N.A., Pastores S.M. Critical care medicine in the United States 2000-2005: an analysis of bed numbers, occupancy rates, payer mix, and costs. Crit. Care Med. 2010, 38:65-71.
51. Hamilton J.R., Overall J.C., Glasgow L.A. Synergistic effect on mortality in mice with murine cytomegalovirus and Pseudomonas aeruginosa, Staphylococcus aureus, or Candida albicans infections. Infect. Immun. 1976, 14:982-989.
52. Hamilton J.R., Overall J.C. Synergistic infection with murine cytomegalovirus and Pseudomonas aeruginosa in mice. J. Infect. Dis. 1978, 137:775-782.
53. Hansen S.G., Powers C.J., Richards R., Ventura A.B., Ford J.C., Siess D., Axthelm M.K., Nelson J.A., Jarvis M.A., Picker L.J., Fruh K. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 2010, 328:102-106.
54. Hayden F.G., Himel H.N., Heggers J.P. Herpesvirus infections in burn patients. Chest 1994, 106:15S-21S. discussion 34S-35S.
55. Hebart H., Einsele H. Diagnosis and treatment of cytomegalovirus infection. Curr. Opin. Hematol. 1998, 5:483-487.
56. Heininger A., Jahn G., Engel C., Notheisen T., Unertl K., Hamprecht K. Human cytomegalovirus infections in nonimmunosuppressed critically ill patients. Crit. Care Med. 2001, 29:541-547.
57. Hillyer C.D., Emmens R.K., Zago-Novaretti M., Berkman E.M. Methods for the reduction of transfusion-transmitted cytomegalovirus infection: filtration versus the use of seronegative donor units. Transfusion 1994, 34:929-934.
58. Ho M. Cytomegalovirus Biology and Infection 1982, Plenum Publishing Corporation. second ed.
59. Holtappels R., Simon C.O., Munks M.W., Thomas D., Deegen P., Kuhnapfel B., Daubner T., Emde S.F., Podlech J., Grzimek N.K.A., Oehrlein-Karpi S.A., Hill A.B., Reddehase M.J. Subdominant CD8 T-cell epitopes account for protection against cytomegalovirus independent of immunodomination. J. Virol. 2008, 82:5781-5796.
60. Holtappels R., Thomas D., Podlech J., Reddehase M.J. Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype. J. Virol. 2002, 76:151-164.
61. Hummel M., Abecassis M.M. A model for reactivation of CMV from latency. J. Clin. Virol. 2002, 25(Suppl. 2):S123-S136.
62. Jaber S., Chanques G., Borry J., Souche B., Verdier R., Perrigault P.-F., Eledjam J.-J. Cytomegalovirus infection in critically ill patients: associated factors and consequences. Chest 2005, 127:233-241.
63. Jackson, S.E., Mason, G.M., Wills, M.R., in press. Human cytomegalovirus immunity and immune evasion. Virus Res.
64. Kagan R.J., Naraqi S., Matsuda T., Jonasson O.M. Herpes simplex virus and cytomegalovirus infections in burned patients. J. Trauma 1985, 25:40-45.
65. Kalil A.C., Florescu D.F. Prevalence and mortality associated with cytomegalovirus infections in non-immunosuppressed ICU patients. Crit. Care Med. 2009, 37:2350-2358.
66. Kalil A.C., Sun J., Florescu D.F. The importance of detecting cytomegalovirus infections in studies evaluating new therapies for severe sepsis. Crit. Care Med. 2010, 38:S663-S667. 610.1097/CCM.1090b1013e3181f20319.
67. Kantor G.L., Goldberg L.S., Johnson B.J., Derechin M.M., Barnett E.V. Immunologic abnormalities induced by postperfusion cytomegalovirus infection. Ann. Intern. Med. 1970, 73:553-558.
68. Karrer U., Sierro S., Wagner M., Oxenius A., Hengel H., Koszinowski U.H., Phillips R.E., Klenerman P. Memory inflation: continuous accumulation of antiviral CD8+ T cells over time. J. Immunol. 2003, 170:2022-2029.
69. Karrer U., Wagner M., Sierro S., Oxenius A., Hengel H., Dumrese T., Freigang S., Koszinowski U.H., Phillips R.E., Klenerman P. Expansion of protective CD8+ T-cell responses driven by recombinant cytomegaloviruses. J. Virol. 2004, 78:2255-2264.
70. Kern F., Bunde T., Faulhaber N., Kiecker F., Khatamzas E., Rudawski I.M., Pruss A., Gratama J.W., Volkmer-Engert R., Ewert R., Reinke P., Volk H.D., Picker Louis J. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J. Infect. Dis. 2002, 185:1709-1716.
71. Kern F., Faulhaber N., Frömmel C., Khatamzas E., Prösch S., Schönemann C., Kretzschmar I., Volkmer-Engert R., Volk H.-D., Reinke P. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur. J. Immunol. 2000, 30:1676-1682.
72. Khan N., Best D., Bruton R., Nayak L., Rickinson A.B., Moss P.A.H. T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection. J. Immunol. 2007, 178:4455-4465.
73. Khan N., Hislop A., Gudgeon N., Cobbold M., Khanna R., Nayak L., Rickinson A.B., Moss P.A. Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J. Immunol. 2004, 173:7481-7489.
74. Khan N., Shariff N., Cobbold M., Bruton R., Ainsworth J.A., Sinclair A.J., Nayak L., Moss P.A.H. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J. Immunol. 2002, 169:1984-1992.
75. Koffron A.J., Hummel M., Patterson B.K., Yan S., Kaufman D.B., Fryer J.P., Stuart F.P., Abecassis M.I. Cellular localization of latent murine cytomegalovirus. J. Virol. 1998, 72:95-103.
76. Kurz S., Steffens H.P., Mayer A., Harris J.R., Reddehase M.J. Latency versus persistence or intermittent recurrences: evidence for a latent state of murine cytomegalovirus in the lungs. J. Virol. 1997, 71:2980-2987.
77. Kutza A.S., Muhl E., Hackstein H., Kirchner H., Bein G. High incidence of active cytomegalovirus infection among septic patients. Clin. Infect. Dis. 1998, 26:1076-1082.
78. Lawson C.M., Grundy J.E., Shellam G.R. Antibody responses to murine cytomegalovirus in genetically resistant and susceptible strains of mice. J. Gen. Virol. 1988, 69:1987-1998.
79. Lemmermann, N.A.W., Böhm, V., Holtappels, R., Reddehase, M.J., in press. In vivo impact of cytomegalovirus evasion of CD8 T-cell immunity: facts and thoughts based on murine models. Virus Res.
80. Lenac T., Arapović J., Traven L., Krmpotić A., Jonjić S. Murine cytomegalovirus regulation of NKG2D ligands. Med. Microbiol. Immunol. 2008, 197:159-166.
81. Lerner P.I., Sampliner J.E. Transfusion-associated cytomegalovirus mononucleosis. Ann. Surg. 1977, 185:406-410.
82. Limaye A.P., Kirby K.A., Rubenfeld G.D., Leisenring W.M., Bulger E.M., Neff M.J., Gibran N.S., Huang M.-L., Santo Hayes T.K., Corey L., Boeckh M. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008, 300:413-422.
83. Linssen C.F.M., Jacobs J.A., Stelma F.F., Mook W.N.K.A., Terporten P., Vink C., Drent M., Bruggeman C.A., Smismans A. Herpes simplex virus load in bronchoalveolar lavage fluid is related to poor outcome in critically ill patients. Intensive Care Med. 2008, 34:2202-2209.
84. Lopez C., Simmons R.L., Mauer S.M., Najarian J.S., Good R.A. Association of renal allograft rejection with virus infections. Am. J. Med. 1974, 56:280-289.
85. Luyt C.-E., Combes A., Deback C., Aubriot-Lorton M.-H., Nieszkowska A., Trouillet J.-L., Capron F., Agut H., Gibert C., Chastre J. Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation. Am. J. Respir. Crit. Care Med. 2007, 175:935-942.
86. Munks M.W., Cho K.S., Pinto A.K., Sierro S., Klenerman P., Hill A.B. Four distinct patterns of memory CD8 T cell responses to chronic murine cytomegalovirus infection. J. Immunol. 2006, 177:450-458.
87. Munks M.W., Gold M.C., Zajac A.L., Doom C.M., Morello C.S., Spector D.H., Hill A.B. Genome-wide analysis reveals a highly diverse CD8 T cell response to murine cytomegalovirus. J. Immunol. 2006, 176:3760-3766.
88. Musiani M., Zerbini M., Zauli D., Cometti G., La Placa M. Impairment of cytomegalovirus and host balance in elderly subjects. J. Clin. Pathol. 1988, 41:722-725.
89. Nagington J. Cytomegalovirus antibody production in renal transplant patients. J. Hyg. 1971, 69:645-660.
90. Olsson J., Wikby A., Johansson B., Löfgren S., Nilsson B.-O., Ferguson F.G. Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. Mech. Ageing Dev. 2001, 121:187-201.
91. Ong G.M., Lowry K., Mahajan S., Wyatt D.E., Simpson C., O'Neill H.J., McCaughey C., Coyle P.V. Herpes simplex type 1 shedding is associated with reduced hospital survival in patients receiving assisted ventilation in a tertiary referral intensive care unit. J. Med. Virol. 2004, 72:121-125.
92. Osawa R., Singh N. Cytomegalovirus infection in critically ill patients: a systematic review. Crit. Care 2009, 13:R68.
93. Ouyang Q., Wagner W.M., Wikby A., Walter S., Aubert G., Dodi A.I., Travers P., Pawelec G. Large numbers of dysfunctional CD8+ T lymphocytes bearing receptors for a single dominant CMV epitope in the very old. J. Clin. Immunol. 2003, 23:247-257.
94. Papazian L., Doddoli C., Chetaille B., Gernez Y., Thirion X., Roch A., Donati Y., Bonnety M., Zandotti C., Thomas P. A contributive result of open-lung biopsy improves survival in acute respiratory distress syndrome patients. Crit. Care Med. 2007, 35:755-762.
95. Papazian L., Thomas P., Bregeon F., Garbe L., Zandotti C., Saux P., Gaillat F., Drancourt M., Auffray J.P., Gouin F. Open-lung biopsy in patients with acute respiratory distress syndrome. Anesthesiology 1998, 88:935-944.
96. Pawelec, G., Derhovanessian, E., in press. Role of CMV in immune senescence. Virus Res.
97. Polic B., Hengel H., Krmpotic A., Trgovcich J., Pavic I., Luccaronin P., Jonjic S., Koszinowski U.H. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J. Exp. Med. 1998, 188:1047-1054.
98. Porteous C., Bradley J.A., Hamilton D.N., Ledingham I.M., Clements G.B., Robinson C.G. Herpes simplex virus reactivation in surgical patients. Crit. Care Med. 1984, 12:626-628.
99. Prichard, M.N., Kern, E.R., in press. The search for new therapies for human cytomegalovirus infections. Virus Res.
100. Prosch S., Staak K., Stein J., Liebenthal C., Stamminger T., Volk H.D., Kruger D.H. Stimulation of the Human cytomegalovirus IE enhancer/promoter in HL-60 cells by TNFalpha is mediated via induction of NF-kappaB. Virology 1995, 208:197-206.
101. Prosch S., Wendt C.E., Reinke P., Priemer C., Oppert M., Kruger D.H., Volk H.D., Docke W.D. A novel link between stress and human cytomegalovirus (HCMV) infection: sympathetic hyperactivity stimulates HCMV activation. Virology 2000, 272:357-365.
102. Pyzik M., Gendron-Pontbriand E.-M., Fodil-Cornu N., Vidal S. Self or nonself? That is the question: sensing of cytomegalovirus infection by innate immune receptors. Mamm. Genome 2010, 1:13.
103. Rawlinson W.D., Farrell H.E., Barrell B.G. Analysis of the complete DNA sequence of murine cytomegalovirus. J. Virol. 1996, 70:8833-8849.
104. Razonable R.R., Fanning C., Brown R.A., Espy M.J., Rivero A., Wilson J., Kremers W., Smith T.F., Paya C.V. Selective reactivation of human herpesvirus 6 variant a occurs in critically ill immunocompetent hosts. J. Infect. Dis. 2002, 185:110-113.
105. Reddehase M.J., Balthesen M., Rapp M., Jonjic S., Pavic I., Koszinowski U.H. The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J. Exp. Med. 1994, 179:185-193.
106. Reddehase M.J., Koszinowski U.H. Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection. Nature 1984, 312:369-371.
107. Reddehase M.J., Podlech J., Grzimek N.K. Mouse models of cytomegalovirus latency: overview. J Clin Virol 2002, 25(Suppl. 2):S23-S36.
108. Reddehase M.J., Weiland F., Munch K., Jonjic S., Luske A., Koszinowski U.H. Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J. Virol. 1985, 55:264-273.
109. Reeves M.B., Sinclair J.H. Human cytomegalovirus. Current Topics in Microbiology and Immunology 2008, 297-313. Springer-Verlag, Heidelberg. T. Shenk, M.F. Stinski (Eds.).
110. Roberts E.T., Haan M.N., Dowd J.B., Aiello A.E. Cytomegalovirus antibody levels, inflammation, and mortality among elderly latinos over 9 years of follow-up. Am. J. Epidemiol. 2010, 172:363-371.
111. Rolle A., Olweus J. Dendritic cells in cytomegalovirus infection: viral evasion and host countermeasures. APMIS 2009, 117:413-426.
112. Ross Shannon A., Arora N., Novak Z., Fowler Karen B., Britt William J., Boppana Suresh B. Cytomegalovirus reinfections in healthy seroimmune women. J. Infect. Dis. 2010, 201:386-389.
113. Salem H.K., Ranjzad P., Driessen A., Appleby C.E., Heagerty A.M., Kingston P.A. Beta-adrenoceptor blockade markedly attenuates transgene expression from cytomegalovirus promoters within the cardiovascular system. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2267-2274.
114. Schrier R.D., Nelson J.A., Oldstone M.B. Detection of human cytomegalovirus in peripheral blood lymphocytes in a natural infection. Science 1985, 230:1048-1051.
115. Schuller D. Lower respiratory tract reactivation of herpes simplex virus. Comparison of immunocompromised and immunocompetent hosts. Chest 1994, 106:3S-7S. discussion 34S-35S.
116. Sierro S., Rothkopf R., Klenerman P. Evolution of diverse antiviral CD8+ T cell populations after murine cytomegalovirus infection. Eur. J. Immunol. 2005, 35:1113-1123.
117. Simmons R.L., Matas A.J., Rattazzi L.C., Balfour H.H., Howard J.R., Najarian J.S. Clinical characteristics of the lethal cytomegalovirus infection following renal transplantation. Surgery 1977, 82:537-546.
118. Simon C.O., Holtappels R., Tervo H.-M., Bohm V., Daubner T., Oehrlein-Karpi S.A., Kuhnapfel B., Renzaho A., Strand D., Podlech J., Reddehase M.J., Grzimek N.K.A. CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J. Virol. 2006, 80:10436-10456.
119. Simoons-Smit A.M., Kraan E.M., Beishuizen A., Strack van Schijndel R.J., Vandenbroucke-Grauls C.M. Herpes simplex virus type 1 and respiratory disease in critically-ill patients: real pathogen or innocent bystander?. Clin. Microbiol. Infect. 2006, 12:1050-1059.
120. Soderberg-Naucler C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer?. J. Intern. Med. 2006, 259:219-246.
121. Soderberg-Naucler C., Fish K.N., Nelson J.A. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997, 91:119-126.
122. Stadler Laura P., Bernstein David I., Callahan S.T., Ferreira J., Simone Gorgone, Gina A., Edwards Kathryn M., Stanberry Lawrence R., Rosenthal Susan L. Seroprevalence of cytomegalovirus (CMV) and risk factors for infection in adolescent males. Clin. Infect. Dis. 2010, 51:e76-e81.
123. Stanberry Lawrence R., Rosenthal Susan L., Mills L., Succop Paul A., Biro Frank M., Morrow Rhoda A., Bernstein David I. Longitudinal risk of herpes simplex virus (HSV) Type 1, HSV Type 2, and cytomegalovirus infections among young adolescent girls. Clin. Infect. Dis. 2004, 39:1433-1438.
124. Staras S.A.S., Dollard S.C., Radford K.W., Dana Flanders W., Pass R.F., Cannon M.J. Seroprevalence of Cytomegalovirus infection in the United States, 1988-1994. Clin. Infect. Dis. 2006, 43:1143-1151.
125. Stein J., Volk H.D., Liebenthal C., Kruger D.H., Prosch S. Tumour necrosis factor alpha stimulates the activity of the human cytomegalovirus major immediate early enhancer/promoter in immature monocytic cells. J. Gen. Virol. 1993, 74:2333-2338.
126. Steininger C. Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system. Clin. Microbiol. Infect. 2007, 13:953-963.
127. Stephan F., Meharzi D., Ricci S., Fajac A., Clergue F., Bernaudin J.F. Evaluation by polymerase chain reaction of cytomegalovirus reactivation in intensive care patients under mechanical ventilation. Intensive Care Med. 1996, 22:1244-1249.
128. Stevens D.P., Barker L.F., Ketcham A.S., Meyer H.M. Asymptomatic cytomegalovirus infection following blood transfusion in tumor surgery. JAMA 1970, 211:1341-1344.
129. Strandberg T.E., Pitkala K.H., Tilvis R.S. Cytomegalovirus antibody level and mortality among community-dwelling older adults with stable cardiovascular disease. JAMA 2009, 301:380-382.
130. Sylwester A.W., Mitchell B.L., Edgar J.B., Taormina C., Pelte C., Ruchti F., Sleath P.R., Grabstein K.H., Hosken N.A., Kern F., Nelson J.A., Picker L.J. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 2005, 202:673-685.
131. Tanaka K., Koga Y., Kimura G., Nomoto K. Pathogenesis and therapy of cytomegalovirus (CMV)-associated lung disease following anti-CD3 monoclonal antibody treatment in mice with persistent murine CMV in the salivary glands. Transplant. Proc. 1995, 27:499-500.
132. Tanaka K., Koga Y., Lu Y.Y., Zhang X.Y., Wang Y., Kimura G., Nomoto K. Murine cytomegalovirus-associated pneumonitis in the lungs free of the virus. J. Clin. Invest. 1994, 94:1019-1025.
133. Thomas A.C., Forster M.R., Bickerstaff A.A., Zimmerman P.D., Wing B.A., Trgovcich J., Bergdall V.K., Klenerman P., Cook C.H. Occult cytomegalovirus in vivarium-housed mice may influence transplant allograft acceptance. Transplant. Immunol. 2010, 23:86-91.
134. Toorkey C.B., Carrigan D.R. Immunohistochemical detection of an immediate early antigen of human cytomegalovirus in normal tissues. J. Infect. Dis. 1989, 160:741-751.
135. Toro A.I., Ossa J. PCR activity of CMV in healthy CMV-seropositive individuals: does latency need redefinition?. Res. Virol. 1996, 147:233-238.
136. Vescovini R., Biasini C., Fagnoni F.F., Telera A.R., Zanlari L., Pedrazzoni M., Bucci L., Monti D., Medici M.C., Chezzi C., Franceschi C., Sansoni P. Massive load of functional effector CD4+ and CD8+ T cells against cytomegalovirus in very old subjects. J. Immunol. 2007, 179:4283-4291.
137. von Muller L., Klemm A., Durmus N., Weiss M., Suger-Wiedeck H., Schneider M., Hampl W., Mertens T. Cellular immunity and active human cytomegalovirus infection in patients with septic shock. J. Infect. Dis. 2007, 196:1288-1295.
138. von Muller L., Klemm A., Weiss M., Schneider M., Suger-Wiedeck H., Durmus N., Hampl W., Mertens T. Active cytomegalovirus infection in patients with septic shock. Emerg. Infect. Dis. 2006, 12:1517-1522.
139. von Muller L., Mertens T. Human cytomegalovirus infection and antiviral immunity in septic patients without canonical immunosuppression. Med. Microbiol. Immunol. 2008, 197:75-82.
140. Walton S.M., Wyrsch P., Munks M.W., Zimmermann A., Hengel H., Hill A.B., Oxenius A. The dynamics of mouse cytomegalovirus-specific CD4 T cell responses during acute and latent infection. J. Immunol. 2008, 181:1128-1134.
141. Wang G.C., Kao W.H.L., Murakami P., Xue Q.-L., Chiou R.B., Detrick B., McDyer J.F., Semba R.D., Casolaro V., Walston J.D., Fried L.P. Cytomegalovirus infection and the risk of mortality and frailty in older women: a prospective observational cohort study. Am. J. Epidemiol. 2010, 171:1144-1152.
142. Weinberg A., Hodges T.N., Li S., Cai G., Zamora M.R. Comparison of PCR, antigenemia assay, and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation. J. Clin. Microbiol. 2000, 38:768-772.
143. Wiener-Well Y., Yinnon A.M., Singer P., Hersch M. Reactivation of cytomegalovirus in critically sick patients. Isr. Med. Assoc. J. 2006, 8:583-584.
144. Wilkinson G.W.G., Tomasec P., Stanton R.J., Armstrong M., Prod'homme V., Aicheler R., McSharry B.P., Rickards C.R., Cochrane D., Llewellyn-Lacey S., Wang E.C.Y., Griffin C.A., Davison A.J. Modulation of natural killer cells by human cytomegalovirus. J. Clin. Virol. 2008, 41:206-212.
145. Winston D.J., Young J.-A.H., Pullarkat V., Papanicolaou G.A., Vij R., Vance E., Alangaden G.J., Chemaly R.F., Petersen F., Chao N., Klein J., Sprague K., Villano S.A., Boeckh M. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008, 111:5403-5410.
146. Wohl D.A., Zeng D., Stewart P., Glomb N., Alcorn T., Jones S., Handy J., Fiscus S., Weinberg A., Gowda D., van der Horst C. Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies. J. Acquir. Immune Defic. Syndr. 2005, 38:538-544.
147. Ziemann M., Sedemund-Adib B., Reiland P., Schmucker P., Hennig H. Increased mortality in long-term intensive care patients with active cytomegalovirus infection. Crit. Care Med. 2008, 36:3145-3150.